This discussion was recorded on August 18, 2022. This transcript has been edited for clarity.
Robert D. Glatter, MD: Welcome. I'm Dr Robert Glatter, medical advisor for Medscape Emergency Medicine. Today, we'll be discussing the topic of Paxlovid rebound, which has been front and center in the news. Both Dr Fauci and President Biden experienced the phenomenon.
Joining us to discuss the topic is Dr Paul Auwaerter, professor of medicine and clinical director, Division of Infectious Diseases at Johns Hopkins University School of Medicine.
Welcome, Paul.
Paul G. Auwaerter, MD: I'm glad to be here. This is a topic many patients and physicians have questions about.
Glatter: Absolutely. I want to start off by defining for the audience what Paxlovid rebound is and how you would explain that.
Auwaerter: Right. I would divide it into two possible areas. One would be that people improve and then have some symptoms of recurrence, whether it's upper respiratory, lower respiratory, or perhaps fever. Does the syndrome recur?
The other would be, for those who especially have at-home antigen tests in hand, where we know that measures about 105or higher logs of the virus, does your test become negative and turn positive? Or does your test still stay positive (for those who haven't checked after taking a course of Paxlovid), usually 2-3 days after you stop, for up to a week later?
COMMENTARY
Paxlovid Rebound in COVID-19: Where We Stand on Drug Regimens
Robert D. Glatter, MD; Paul G. Auwaerter, MD
DisclosuresSeptember 01, 2022
This discussion was recorded on August 18, 2022. This transcript has been edited for clarity.
Robert D. Glatter, MD: Welcome. I'm Dr Robert Glatter, medical advisor for Medscape Emergency Medicine. Today, we'll be discussing the topic of Paxlovid rebound, which has been front and center in the news. Both Dr Fauci and President Biden experienced the phenomenon.
Joining us to discuss the topic is Dr Paul Auwaerter, professor of medicine and clinical director, Division of Infectious Diseases at Johns Hopkins University School of Medicine.
Welcome, Paul.
Paul G. Auwaerter, MD: I'm glad to be here. This is a topic many patients and physicians have questions about.
Glatter: Absolutely. I want to start off by defining for the audience what Paxlovid rebound is and how you would explain that.
Auwaerter: Right. I would divide it into two possible areas. One would be that people improve and then have some symptoms of recurrence, whether it's upper respiratory, lower respiratory, or perhaps fever. Does the syndrome recur?
The other would be, for those who especially have at-home antigen tests in hand, where we know that measures about 105or higher logs of the virus, does your test become negative and turn positive? Or does your test still stay positive (for those who haven't checked after taking a course of Paxlovid), usually 2-3 days after you stop, for up to a week later?
Medscape Emergency Medicine © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Robert D. Glatter, Paul G. Auwaerter. Paxlovid Rebound in COVID-19: Where We Stand on Drug Regimens - Medscape - Sep 01, 2022.
Tables
Authors and Disclosures
Authors and Disclosures
Author(s)
Robert D. Glatter, MD
Assistant Professor of Emergency Medicine, Department of Emergency Medicine, Zucker School of Medicine at Hofstra/Northwell, New York, NY
Disclosure: Robert D. Glatter, MD, has disclosed no relevant financial relationships.
Paul G. Auwaerter, MD
Professor of Medicine, Sherrilyn and Ken Fisher Professor of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine; Clinical Director, Division of Infectious Diseases, Johns Hopkins Hospital, Baltimore, Maryland
Disclosure: Paul G. Auwaerter, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Infectious Diseases Society of America Foundation (Chair); American Lyme Disease Foundation (Board Member)
Received income in an amount equal to or greater than $250 from: Humanigen (DSMB); Verily (scientific consulting); Pfizer (scientific consulting)